Cargando…
The characteristics and novel clinical implications of CD4+CXCR5+Foxp3+ follicular regulatory T cells in breast cancer
BACKGROUND: Follicular regulatory T cells (Tfr) are a subset of regulatory T cells (Tregs) that suppress the humoral immune response in the germinal center. They are associated with increased rates of disease stabilization and decreased autoantibody levels in a variety of tumor and autoimmune diseas...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422094/ https://www.ncbi.nlm.nih.gov/pubmed/34532469 http://dx.doi.org/10.21037/atm-21-3848 |
_version_ | 1783749217779449856 |
---|---|
author | Miao, Xianyuan Guo, Qiusheng Pan, Zhiwen Xu, Xiaohong Shao, Xiying Wang, Xiaojia |
author_facet | Miao, Xianyuan Guo, Qiusheng Pan, Zhiwen Xu, Xiaohong Shao, Xiying Wang, Xiaojia |
author_sort | Miao, Xianyuan |
collection | PubMed |
description | BACKGROUND: Follicular regulatory T cells (Tfr) are a subset of regulatory T cells (Tregs) that suppress the humoral immune response in the germinal center. They are associated with increased rates of disease stabilization and decreased autoantibody levels in a variety of tumor and autoimmune diseases. The binding of T-cell immunoglobulin mucin 3 (TIM-3) and its ligand on the surface of Tfr cells could result in the depletion of T lymphocytes and the termination of the immune response mediated by helper T cell 1. However, the role of Tfr cells in breast cancer (BC) remains unclear. METHODS: In this study, we detected the expression of CD4+CXCR5+Foxp3+Tfr cells in the peripheral blood of 35 BC patients and 30 healthy control patients by flow cytometry, and analyzed the relationship between Tfr cells and the clinical characteristics of patients. In addition, the expression of TIM-3 on the surface of Tfr cells in 6 triple-negative BC (TNBC) patients was further investigated using mass spectrometry. RESULTS: We found a significant increase in Tfr cells in BC patients compared to healthy control patients (23.47%±9.70% vs. 10.99%±4.68%; P=0.001). Notably, the increase was more significant in early stage than advanced stage TNBC patients (28.52%±10.75% vs. 18.69%±5.19%; P=0.006), and there was a negative correlation between Tfr cells and serum lactate dehydrogenase (LDH) in early stage TNBC patients (r=−0.585; P=0.008). Additionally, we found that the expression of Tfr cells was higher in TNBC patients than luminal BC patients (28.25%±10.11% vs. 18.5%±8.15%; P=0.028); however, there was no significant difference in expression in hormone receptor positive (HR+) BC and hormone receptor negative (HR−) BC (P=0.141) patients. Notably, the surface of Tfr cells of TNBC patients had higher levels of TIM-3 expression than those of healthy control patients (3.93±0.92 vs. 2.65±0.15, respectively; t=−3.02; P<0.05), which the mass spectrometry showed were positively correlated with the intracellular Foxp3 expression of Tfr cells (r=0.82; P=0.036). CONCLUSIONS: Our results suggest that circulating Tfr cells and the expression of TIM-3 were significantly increased in BC patients, which were related to stage and histological type, and may be involved in the pathogenesis of BC. |
format | Online Article Text |
id | pubmed-8422094 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-84220942021-09-15 The characteristics and novel clinical implications of CD4+CXCR5+Foxp3+ follicular regulatory T cells in breast cancer Miao, Xianyuan Guo, Qiusheng Pan, Zhiwen Xu, Xiaohong Shao, Xiying Wang, Xiaojia Ann Transl Med Original Article BACKGROUND: Follicular regulatory T cells (Tfr) are a subset of regulatory T cells (Tregs) that suppress the humoral immune response in the germinal center. They are associated with increased rates of disease stabilization and decreased autoantibody levels in a variety of tumor and autoimmune diseases. The binding of T-cell immunoglobulin mucin 3 (TIM-3) and its ligand on the surface of Tfr cells could result in the depletion of T lymphocytes and the termination of the immune response mediated by helper T cell 1. However, the role of Tfr cells in breast cancer (BC) remains unclear. METHODS: In this study, we detected the expression of CD4+CXCR5+Foxp3+Tfr cells in the peripheral blood of 35 BC patients and 30 healthy control patients by flow cytometry, and analyzed the relationship between Tfr cells and the clinical characteristics of patients. In addition, the expression of TIM-3 on the surface of Tfr cells in 6 triple-negative BC (TNBC) patients was further investigated using mass spectrometry. RESULTS: We found a significant increase in Tfr cells in BC patients compared to healthy control patients (23.47%±9.70% vs. 10.99%±4.68%; P=0.001). Notably, the increase was more significant in early stage than advanced stage TNBC patients (28.52%±10.75% vs. 18.69%±5.19%; P=0.006), and there was a negative correlation between Tfr cells and serum lactate dehydrogenase (LDH) in early stage TNBC patients (r=−0.585; P=0.008). Additionally, we found that the expression of Tfr cells was higher in TNBC patients than luminal BC patients (28.25%±10.11% vs. 18.5%±8.15%; P=0.028); however, there was no significant difference in expression in hormone receptor positive (HR+) BC and hormone receptor negative (HR−) BC (P=0.141) patients. Notably, the surface of Tfr cells of TNBC patients had higher levels of TIM-3 expression than those of healthy control patients (3.93±0.92 vs. 2.65±0.15, respectively; t=−3.02; P<0.05), which the mass spectrometry showed were positively correlated with the intracellular Foxp3 expression of Tfr cells (r=0.82; P=0.036). CONCLUSIONS: Our results suggest that circulating Tfr cells and the expression of TIM-3 were significantly increased in BC patients, which were related to stage and histological type, and may be involved in the pathogenesis of BC. AME Publishing Company 2021-08 /pmc/articles/PMC8422094/ /pubmed/34532469 http://dx.doi.org/10.21037/atm-21-3848 Text en 2021 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Original Article Miao, Xianyuan Guo, Qiusheng Pan, Zhiwen Xu, Xiaohong Shao, Xiying Wang, Xiaojia The characteristics and novel clinical implications of CD4+CXCR5+Foxp3+ follicular regulatory T cells in breast cancer |
title | The characteristics and novel clinical implications of CD4+CXCR5+Foxp3+ follicular regulatory T cells in breast cancer |
title_full | The characteristics and novel clinical implications of CD4+CXCR5+Foxp3+ follicular regulatory T cells in breast cancer |
title_fullStr | The characteristics and novel clinical implications of CD4+CXCR5+Foxp3+ follicular regulatory T cells in breast cancer |
title_full_unstemmed | The characteristics and novel clinical implications of CD4+CXCR5+Foxp3+ follicular regulatory T cells in breast cancer |
title_short | The characteristics and novel clinical implications of CD4+CXCR5+Foxp3+ follicular regulatory T cells in breast cancer |
title_sort | characteristics and novel clinical implications of cd4+cxcr5+foxp3+ follicular regulatory t cells in breast cancer |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422094/ https://www.ncbi.nlm.nih.gov/pubmed/34532469 http://dx.doi.org/10.21037/atm-21-3848 |
work_keys_str_mv | AT miaoxianyuan thecharacteristicsandnovelclinicalimplicationsofcd4cxcr5foxp3follicularregulatorytcellsinbreastcancer AT guoqiusheng thecharacteristicsandnovelclinicalimplicationsofcd4cxcr5foxp3follicularregulatorytcellsinbreastcancer AT panzhiwen thecharacteristicsandnovelclinicalimplicationsofcd4cxcr5foxp3follicularregulatorytcellsinbreastcancer AT xuxiaohong thecharacteristicsandnovelclinicalimplicationsofcd4cxcr5foxp3follicularregulatorytcellsinbreastcancer AT shaoxiying thecharacteristicsandnovelclinicalimplicationsofcd4cxcr5foxp3follicularregulatorytcellsinbreastcancer AT wangxiaojia thecharacteristicsandnovelclinicalimplicationsofcd4cxcr5foxp3follicularregulatorytcellsinbreastcancer AT miaoxianyuan characteristicsandnovelclinicalimplicationsofcd4cxcr5foxp3follicularregulatorytcellsinbreastcancer AT guoqiusheng characteristicsandnovelclinicalimplicationsofcd4cxcr5foxp3follicularregulatorytcellsinbreastcancer AT panzhiwen characteristicsandnovelclinicalimplicationsofcd4cxcr5foxp3follicularregulatorytcellsinbreastcancer AT xuxiaohong characteristicsandnovelclinicalimplicationsofcd4cxcr5foxp3follicularregulatorytcellsinbreastcancer AT shaoxiying characteristicsandnovelclinicalimplicationsofcd4cxcr5foxp3follicularregulatorytcellsinbreastcancer AT wangxiaojia characteristicsandnovelclinicalimplicationsofcd4cxcr5foxp3follicularregulatorytcellsinbreastcancer |